CompletedPhase 2NCT01265888
Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl.
Studying Idiopathic pulmonary fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Geno LLC
- Principal Investigator
- Gregory SuplickGeno LLC
- Intervention
- Inhaled Nitric Oxide(drug)
- Enrollment
- 31 enrolled
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2011 – 2016
Study locations (10)
- University of Alabama @ Birmingham, Birmingham, Alabama, United States
- VA Greater LA Health Care System-UCLA, Los Angeles, California, United States
- University of California- Davis Medical Center, Sacramento, California, United States
- National Jewish Health, Denver, Colorado, United States
- Kentuckiana Pulmonary Associates, Louisville, Kentucky, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- University of Medicine and Dentistry of New Jersey, Newark, New Jersey, United States
- Ohio State University, Martha Morehouse Medical Plaza, Columbus, Ohio, United States
- UT Southwestern Medical Center, Dallas, Texas, United States
- University of Utah, Salt Lake City, Utah, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01265888 on ClinicalTrials.govOther trials for Idiopathic pulmonary fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT05988463Dose-Escalation Study of Artesunate Patients With IPFJoseph C. Wu
- RECRUITINGPHASE2NCT07572383Advanced Imaging to Assess the Effect of Immunosuppression on Progressive FibrosisPeter Caravan
- RECRUITINGNANCT07482917Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 TrialHospital de Granollers
- RECRUITINGNANCT07486206Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 TrialHospital de Granollers
- RECRUITINGPHASE2NCT06241560A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the BloodBoehringer Ingelheim
- RECRUITINGPHASE3NCT07201922A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary FibrosisBoehringer Ingelheim
- RECRUITINGPHASE2NCT06968845A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary FibrosisRein Therapeutics
- ENROLLING BY INVITATIONNCT06885515Telomeres Length in Israeli Fibrotic ILD PatientsBarzilai Medical Center